JP2018518527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518527A5 JP2018518527A5 JP2017567429A JP2017567429A JP2018518527A5 JP 2018518527 A5 JP2018518527 A5 JP 2018518527A5 JP 2017567429 A JP2017567429 A JP 2017567429A JP 2017567429 A JP2017567429 A JP 2017567429A JP 2018518527 A5 JP2018518527 A5 JP 2018518527A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- allogeneic
- cell population
- human patient
- cmv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185558P | 2015-06-26 | 2015-06-26 | |
| US62/185,558 | 2015-06-26 | ||
| US201562191304P | 2015-07-10 | 2015-07-10 | |
| US62/191,304 | 2015-07-10 | ||
| PCT/US2016/038530 WO2016209816A1 (en) | 2015-06-26 | 2016-06-21 | Methods of treating cmv retinitis by t cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018518527A JP2018518527A (ja) | 2018-07-12 |
| JP2018518527A5 true JP2018518527A5 (enExample) | 2019-08-08 |
Family
ID=56404300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567429A Pending JP2018518527A (ja) | 2015-06-26 | 2016-06-21 | Ｔ細胞療法によるｃｍｖ網膜炎の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10342864B2 (enExample) |
| EP (2) | EP3756676B1 (enExample) |
| JP (1) | JP2018518527A (enExample) |
| CN (1) | CN107921065A (enExample) |
| HK (1) | HK1254397A1 (enExample) |
| WO (1) | WO2016209816A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2812431B1 (en) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| EP3700553A1 (en) | 2017-10-23 | 2020-09-02 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| EP3765602A1 (en) | 2018-03-14 | 2021-01-20 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
| CN113924331B (zh) * | 2019-05-28 | 2024-09-13 | 东洋纺株式会社 | 聚酯薄膜、层叠薄膜及其用途 |
| WO2021021937A1 (en) * | 2019-07-29 | 2021-02-04 | Baylor College Of Medicine | Antigen-specific t cell banks and methods of making and using the same therapeutically |
| RU2740943C1 (ru) * | 2020-03-23 | 2021-01-21 | Борис Сергеевич Першин | Способ лечения цитомегаловирусного ретинита после трансплантации гемопоэтических стволовых клеток |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595978A (en) * | 1990-08-16 | 1997-01-21 | Isis Pharmaceuticals, Inc. | Composition and method for treatment of CMV retinites |
| ATE229810T1 (de) * | 1996-10-11 | 2003-01-15 | Univ California | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| US6156317A (en) | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US7041442B1 (en) | 1999-06-04 | 2006-05-09 | Florian Kern | Peptides for vaccinating against human CMV |
| US6555675B2 (en) * | 2000-08-21 | 2003-04-29 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists |
| DE60109633T2 (de) | 2000-10-20 | 2006-01-19 | City Of Hope, Duarte | Immunreaktive peptidische ctl-epitope aus dem menschlichen cytomegalovirus pp150 |
| US7718196B2 (en) | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| JP2005517637A (ja) * | 2001-11-29 | 2005-06-16 | セラコス・インコーポレイテッド | 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法 |
| EP1483575A2 (en) | 2002-02-28 | 2004-12-08 | Intercell AG | Methods for isolating ligands e.g. t cell epitopes |
| US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| MX2011005691A (es) | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB0917094D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US20140303092A1 (en) * | 2011-10-26 | 2014-10-09 | Chimerix, Inc | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| GB201121308D0 (en) * | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| WO2017003763A1 (en) * | 2015-06-27 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Methods of treating glioblastoma multiforme by t cell therapy |
-
2016
- 2016-06-21 HK HK18113474.8A patent/HK1254397A1/zh unknown
- 2016-06-21 EP EP20190952.0A patent/EP3756676B1/en active Active
- 2016-06-21 EP EP16736962.8A patent/EP3313419B1/en active Active
- 2016-06-21 CN CN201680049106.8A patent/CN107921065A/zh active Pending
- 2016-06-21 JP JP2017567429A patent/JP2018518527A/ja active Pending
- 2016-06-21 WO PCT/US2016/038530 patent/WO2016209816A1/en not_active Ceased
- 2016-06-24 US US15/191,773 patent/US10342864B2/en active Active
-
2019
- 2019-05-23 US US16/420,876 patent/US11103577B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | Hepatitis B functional cure and immune response | |
| Saez-Cirion et al. | Immunometabolism and HIV-1 pathogenesis: food for thought | |
| Archin et al. | Eradicating HIV-1 infection: seeking to clear a persistent pathogen | |
| Gattinoni et al. | T memory stem cells in health and disease | |
| Luo et al. | B cell response to vaccination | |
| Liu et al. | HIV-1 functional cure: will the dream come true? | |
| Hütter | Stem cell transplantation in strategies for curing HIV/AIDS | |
| Ng et al. | IL-10: achieving balance during persistent viral infection | |
| JP2017515901A5 (enExample) | ||
| Pannetier et al. | Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus | |
| Kamphorst et al. | Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity | |
| JP2018524335A (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| JP2019512020A5 (enExample) | ||
| Ahluwalia et al. | Infection and immune memory: variables in robust protection by vaccines against SARS-CoV-2 | |
| Ravens et al. | Human γδ T cell receptor repertoires in peripheral blood remain stable despite clearance of persistent hepatitis C virus infection by direct-acting antiviral drug therapy | |
| JP2018520095A5 (enExample) | ||
| Wang et al. | Tissue-resident memory-like ILCs: innate counterparts of TRM cells | |
| JP2014512391A5 (enExample) | ||
| JP2012532624A5 (enExample) | ||
| Hemann et al. | Plasmacytoid dendritic cells require direct infection to sustain the pulmonary influenza A virus-specific CD8 T cell response | |
| Kavazović et al. | Cheating the hunger games; mechanisms controlling clonal diversity of CD8 effector and memory populations | |
| Martin et al. | Influence of time and number of antigen encounters on memory CD8 T cell development | |
| Kotton et al. | Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023 | |
| Marras et al. | Baseline and dynamic expression of activating NK cell receptors in the control of chronic viral infections: the paradigm of HIV-1 and HCV | |
| Conway et al. | Cellular therapies for the treatment and prevention of SARS-CoV-2 infection |